Proposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with mu ...
Continued strong financial results and cash generation GAAP EPS up 25%, Adjusted EPS up 10% GAAP Operating Cash Flows up 37%, Adjusted Free Cash Flow (including swaps) up 83% Returned $161 million to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results